Yang Sheng, deputy director of the State Drug Administration, explained at a press conference on the theme of the “Getting Started” series held by the State Information Office on the 20th that the State Drug Administration will promote the implementation of a drug test data protection system and establish a market monopoly period for children's drugs, drugs for rare diseases, etc., so that companies' investment in R&D is more secure. Improve communication mechanisms for early R&D, strengthen advance guidance on new targets and innovative drugs with new mechanisms, so that enterprises can take fewer detours in R&D. Expand the “Spring Rain Campaign” to transform clinical innovation results in medical devices, formulate clinical trial and evaluation guidelines in cutting-edge fields such as brain-computer interfaces, and pave the way for future industries.

Yang Sheng, deputy director of the State Drug Administration, explained at a press conference on the theme of the “Getting Started” series held by the State Information Office on the 20th that the State Drug Administration will promote the implementation of a drug test data protection system and establish a market monopoly period for children's drugs, drugs for rare diseases, etc., so that companies' investment in R&D is more secure. Improve communication mechanisms for early R&D, strengthen advance guidance on new targets and innovative drugs with new mechanisms, so that enterprises can take fewer detours in R&D. Expand the “Spring Rain Campaign” to transform clinical innovation results in medical devices, formulate clinical trial and evaluation guidelines in cutting-edge fields such as brain-computer interfaces, and pave the way for future industries.